An independent console on the GLOW research record

What Pharmacy Glow is

Pharmacy Glow is an independent editorial project that publishes summaries of the peer-reviewed research literature on the GLOW peptide blend and its three constituents — GHK-Cu, BPC-157 and TB-500. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The site is built as a console for a reason. GLOW is not one molecule but a co-formulated trio with three distinct mechanisms and three distinct bodies of evidence, and a console is the surface that can read each leg against its own literature without collapsing the differences. Where the evidence is constituent-level and preclinical, we say so. Where there is no blend-level human trial, we mark the gap rather than paper over it.

Why 'pharmacy' is in the name

The word 'pharmacy' in this domain is editorial framing — a position this publisher occupies relative to the literature and the access landscape — not a claim about services we provide. We do not fill prescriptions, dispense, compound, or supply anything, and nothing on this site is for sale. We do not run a pharmacy and we are not affiliated with one.

What the name signals is the register: a medicinal-access reading that takes the regulatory boundary seriously. That is why this site carries a dedicated legal-status page that reads the FDA 503A position on the blend's constituents directly from the FDA record, and frames it as general information rather than legal advice.

How we source

Every quantitative claim on this site resolves to a citation on the references page — PubMed, PMC, peer-reviewed journals, and, for the regulatory material, FDA.gov pages and authoritative legal analysis. We use generic compound names only and do not name vendors, clinics, or brands. When the literature on the constituents is concentrated in a small number of research groups, or relies on full-length thymosin beta-4 rather than the TB-500 fragment, we flag that limitation in the text rather than leave it implied.